ARS Pharmaceuticals (SPRY) News Today

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares are under pressure as a wave of law-firm notices highlights a securities class-action lawsuit and an upcoming lead-plaintiff deadline. The legal developments appear to be the main negative catalyst behind the stock’s decline and its proximity to a 12-month low.

• Negative Sentiment: Several firms, including Kaplan Fox, Rosen Law Firm, Pomerantz and Faruqi & Faruqi, publicized a securities class action against ARS Pharmaceuticals. The case covers investors who purchased shares between March 9 and June 24, 2026, and alleges violations of U.S. securities laws. The allegations have not been proven. Kaplan Fox class action announcement
• Negative Sentiment: The lawsuit alleges that ARS’s statements regarding a July 1, 2026 CVS Caremark formulary coverage date were overly confident and did not adequately warn that the decision could be delayed until January 2027. The coverage delay allegedly contributed to a $2.52-per-share loss and a 23.9% single-day stock decline, increasing potential liability and investor uncertainty. Levi and Korsinsky investor alert
• Neutral Sentiment: Investors who acquired shares during the class period have until October 5, 2026 to seek appointment as lead plaintiff. The deadline itself does not establish liability, but repeated reminders may keep litigation concerns in focus and contribute to volatility. Rosen Law Firm deadline notice

The legal overhang comes as SPRY trades well below its 50-day and 200-day moving averages, suggesting that investors remain cautious about the company’s commercial outlook and potential litigation exposure.